This close brings the total capital raised in the round to $11M, fueling IgniteData's expansion of its global research site network, advancement of its flagship product, Archer, and acceleration of innovation in generative AI-powered data automation.

The round was led by FCA Venture Partners, with the Labcorp Venture Fund and Epsilon anchoring the final close as the primary investors. Strong participation also came from existing investors, including SpringTide and Oncology Ventures, alongside a group of distinguished new investors bringing unparalleled industry experience.

IgniteData is on a mission to revolutionize clinical trials through intelligent automation. By enabling real-time, secure transfer of clinical data between healthcare providers and life science companies, IgniteData accelerates research while reducing burden on clinical sites. With deployments across premier research centers, partnerships with top pharmaceutical sponsors, and cutting-edge use of generative AI and intelligent data mapping, IgniteData is redefining what's possible in clinical trial operations.